Grupo de investigación GRINCAR, Departamento de Ciencias da Saúde, Facultade de Enfermaría e Podoloxía, Universidade da Coruña, 15471 Ferrol, Spain.
Grupo de investigación GRINCAR, Departamento de Ciencias da Saúde, Facultade de Enfermaría e Podoloxía, Universidade da Coruña, 15471 Ferrol, Spain.
Health Policy. 2018 Dec;122(12):1316-1325. doi: 10.1016/j.healthpol.2018.08.014. Epub 2018 Aug 31.
In Spain, the use of generics has considerably evolved in a short period of time through different anti-crisis legislation changes. Before the financial crisis the proposal of generics was an option for patients. Nowadays its use is actively enforced by Health authorities.
To explore the perceptions of pharmacists and physicians regarding the generic substitution driven by new Spanish drugs policies as well as their adaptive strategies intended to lessen the impact of changes to their patients' treatment.
Pharmacists (16) and physicians (13) from Ferrol and A Coruña participated in a qualitative study using semi-structured in-depth interviews.
Qualitative analysis allowed identification of nine key components in the substitution process: Enabling factors: 'Adequate information to patients', 'Acute treatments', 'Bioappearance', 'Prescription by Estate Official Denomination followed by laboratory name', 'Personalized dosage systems'. Obstructing factors: 'Generics/Authorities distrust', 'Lack of time', 'Patient characteristics', 'Pharmacy financial management'.
Pharmacists and physicians in our economic crisis context perceive different barriers resulting in difficulties in the generic substitution process. They have implemented strategies to capitalize on the enablers and overcome the additional budget-cut barriers imposed by the Administration that had prevented them from maintaining their patient's treatment preferences. Spanish health authorities could improve current legislation either by reducing the number of new laboratories of authorized generic manufacturers or by extending the pharmacist capability for equivalent drugs substitution.
探讨西班牙新药品政策推动的通用名药物替代的药师和医生的看法，以及他们为减轻患者治疗变化的影响而采取的适应策略。
来自费罗尔和拉科鲁尼亚的 16 名药剂师和 13 名医生参与了这项使用半结构式深入访谈的定性研究。
定性分析确定了替代过程中的九个关键组成部分：促进因素：“向患者提供充分的信息”、“急性治疗”、“生物外观”、“按官方处方名和实验室名称开处方”、“个性化剂量系统”。阻碍因素：“对通用名药物/当局的不信任”、“缺乏时间”、“患者特征”、“药房财务管理”。
在我们的经济危机背景下，药师和医生认为通用名药物替代过程中存在不同的障碍，导致困难。他们已经实施了一些策略，利用促进因素并克服行政部门强加的额外预算削减障碍，这些障碍使他们无法维持患者的治疗偏好。西班牙卫生当局可以通过减少授权通用名药物制造商的新实验室数量或扩大药剂师对等效药物替代的能力来改进现行法规。
